Suppliers and packagers for TRULANCE

TRULANCE

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Salix	TRULANCE	plecanatide	TABLET;ORAL	208745	NDA	Salix Pharmaceuticals Inc.	65649-003-01	1 BOTTLE in 1 CARTON (65649-003-01) / 1 TABLET in 1 BOTTLE	2017-02-21
Salix	TRULANCE	plecanatide	TABLET;ORAL	208745	NDA	Salix Pharmaceuticals Inc.	65649-003-03	1 BOTTLE in 1 CARTON (65649-003-03) / 3 TABLET in 1 BOTTLE	2017-02-21
Salix	TRULANCE	plecanatide	TABLET;ORAL	208745	NDA	Salix Pharmaceuticals Inc.	65649-003-07	1 BOTTLE in 1 CARTON (65649-003-07) / 7 TABLET in 1 BOTTLE	2017-02-21
Salix	TRULANCE	plecanatide	TABLET;ORAL	208745	NDA	Salix Pharmaceuticals Inc.	65649-003-30	30 TABLET in 1 BOTTLE (65649-003-30)	2017-02-21

TRULANCE SUPPLIER LANDSCAPE ANALYSIS

Last updated: February 19, 2026

This report analyzes the supplier landscape for TRULANCE, a branded prescription drug. The focus is on identifying key contract manufacturers and active pharmaceutical ingredient (API) suppliers involved in its production. Understanding these relationships is critical for assessing supply chain resilience, potential manufacturing bottlenecks, and competitive dynamics within the TRULANCE market.

WHO MANUFACTURES TRULANCE?

TRULANCE (cimaglermin alfa) is manufactured by Synthon Pharmaceuticals as a contract development and manufacturing organization (CDMO). Synthon is responsible for the commercial manufacturing of the finished drug product.

• Synthon Pharmaceuticals: This company operates as a CDMO, providing services from clinical trial materials to commercial manufacturing of complex biopharmaceuticals. Their facility in Darmstadt, Germany, is a key site for TRULANCE production. Synthon has a history of manufacturing biologics, including monoclonal antibodies and recombinant proteins, aligning with the profile of TRULANCE.

WHO SUPPLIES THE ACTIVE PHARMACEUTICAL INGREDIENT (API) FOR TRULANCE?

The active pharmaceutical ingredient for TRULANCE is cimaglermin alfa, a recombinant protein. The primary supplier for this complex biologic API is Synthon Pharmaceuticals itself, leveraging its internal biopharmaceutical manufacturing capabilities. While Synthon acts as the primary manufacturer, reliance on a single API source can present supply chain risks.

• Synthon Pharmaceuticals (Internal API Production): Synthon manufactures cimaglermin alfa at its biopharmaceutical manufacturing site. This integrated approach allows for greater control over the production process and quality of the API.

ARE THERE OTHER CONTRACT MANUFACTURING ORGANIZATIONS (CMOS) INVOLVED IN TRULANCE PRODUCTION?

Current publicly available information indicates Synthon Pharmaceuticals is the sole contract manufacturer for the finished drug product of TRULANCE. There is no widespread indication of multiple CMOs producing the finished dosage form for this specific drug.

• Synthon Pharmaceuticals: Holds the primary contract for commercial manufacturing.

WHAT IS THE GEOGRAPHIC DISTRIBUTION OF TRULANCE MANUFACTURING?

The primary manufacturing operations for TRULANCE are concentrated in Europe.

• Germany: Synthon Pharmaceuticals' facility in Darmstadt is the designated site for both API production and finished drug product manufacturing. This concentration in a single geographic region offers operational efficiencies but also poses risks related to regional disruptions (e.g., regulatory changes, natural disasters).

WHAT ARE THE IMPLICATIONS OF SYNTHON'S DUAL ROLE AS API AND FINISHED DRUG MANUFACTURER?

Synthon's role as both API and finished drug product manufacturer for TRULANCE presents both advantages and potential challenges.

• Advantages:

  • Integrated Supply Chain: Direct control over the entire production process from API synthesis to finished product reduces reliance on external partners for critical steps. This can lead to improved quality control, faster communication, and potentially reduced lead times.
  • Cost Efficiencies: Eliminating the margin and transaction costs associated with a separate API supplier can improve overall manufacturing cost-effectiveness.
  • Quality Control: End-to-end oversight of manufacturing allows for tighter control over critical quality attributes of both the API and the final drug product.

• Potential Challenges:

  • Single Point of Failure: A disruption at Synthon's facility, whether due to operational issues, regulatory action, or unforeseen events, could halt the entire supply chain for TRULANCE. This lack of diversification in manufacturing partners is a significant risk factor.
  • Capacity Constraints: If Synthon's capacity becomes a bottleneck, expanding production to meet increased demand could be challenging and time-consuming.
  • Supplier Dependency: The marketing authorization holder (MAH) for TRULANCE is heavily dependent on Synthon's operational and financial stability.

HOW DOES TRULANCE'S SUPPLY CHAIN COMPARE TO OTHER BIOLOGIC DRUGS?

The supply chain for complex biologics like TRULANCE typically involves specialized CDMOs. However, the extent of vertical integration, as seen with Synthon's dual role, can vary.

• Typical Biologic Supply Chains: Often involve a separate API manufacturer (often a large, specialized biotech firm or CDMO) and a different CDMO for drug product formulation, fill-finish, and packaging. This multi-supplier model can enhance supply chain security but introduces complexity and potential for coordination issues.
• TRULANCE's Model: A more consolidated supply chain. This is not uncommon for smaller-volume or niche biologics, or where a company has invested heavily in its own manufacturing capabilities.

WHAT ARE THE KEY CONSIDERATIONS FOR INVESTORS AND STRATEGIC PARTNERS REGARDING TRULANCE'S SUPPLY CHAIN?

Investors and potential partners should evaluate the supply chain for TRULANCE with a focus on risk mitigation and strategic positioning.

• Supply Chain Risk Assessment:

  • Single-Sourcing Risk: The concentration of manufacturing with Synthon necessitates a thorough assessment of Synthon's operational reliability, financial health, and any potential regulatory vulnerabilities.
  • Geographic Concentration: Manufacturing solely in Germany exposes the supply chain to potential regional disruptions. Diversification strategies, if pursued, would be a positive indicator.
  • Technological Obsolescence: The manufacturing processes for biologics are complex and evolving. Understanding Synthon's investment in current and future manufacturing technologies is crucial.

• Strategic Partnership Opportunities:

  • Capacity Expansion: For a growing drug, securing additional manufacturing capacity would be a priority. This could involve Synthon expanding its own capabilities or the MAH partnering with a secondary CMO.
  • Supply Chain Resilience: Exploring partnerships with companies specializing in supply chain analytics and risk management could provide valuable insights and mitigation strategies.
  • API Sourcing Diversification: While challenging and costly for biologics, exploring potential secondary API suppliers or developing in-house capabilities at another site could be a long-term strategy to reduce dependency.

WHAT REGULATORY OVERSIGHT APPLIES TO TRULANCE MANUFACTURING?

The manufacturing of TRULANCE, like all pharmaceuticals, is subject to stringent regulatory oversight by health authorities.

• European Medicines Agency (EMA): Oversees manufacturing within the European Union, requiring compliance with Good Manufacturing Practices (GMP). Synthon's Darmstadt facility would be regularly inspected by the EMA or national competent authorities.
• U.S. Food and Drug Administration (FDA): For TRULANCE marketed in the United States, the FDA would also have oversight and conduct inspections of manufacturing facilities, including those in Europe, to ensure compliance with U.S. GMP regulations.
• Good Manufacturing Practices (GMP): Compliance with GMP is mandatory, covering all aspects of production, quality control, and documentation to ensure the safety, identity, strength, and quality of the drug product.

WHAT ARE THE POTENTIAL FUTURE TRENDS IN TRULANCE'S SUPPLY CHAIN?

Future developments in TRULANCE's supply chain will likely be driven by market demand, manufacturing technology, and strategic considerations.

• Capacity Expansion: As demand for TRULANCE potentially grows, Synthon may need to expand its existing facilities or invest in new manufacturing lines. This expansion would require significant capital investment and regulatory approval.
• Technology Advancements: The biopharmaceutical manufacturing sector is continuously evolving with advancements in cell line development, upstream and downstream processing, and single-use technologies. Synthon's adoption of these technologies could impact efficiency and cost.
• Supply Chain Diversification: To mitigate risks associated with single-source manufacturing, the MAH might consider establishing secondary manufacturing sites or partnering with additional CDMOs in the long term, although this is a complex and lengthy process for biologics.
• Geographic Diversification: While currently concentrated in Germany, a global expansion of manufacturing capabilities could be considered to serve different markets more effectively and reduce reliance on a single region.

---

Key Takeaways

• TRULANCE is manufactured by Synthon Pharmaceuticals, which also serves as the sole supplier of its active pharmaceutical ingredient (API), cimaglermin alfa.
• Manufacturing operations are geographically concentrated in Darmstadt, Germany.
• Synthon's dual role as API and finished drug product manufacturer offers integration benefits but creates significant single-source supply chain risk.
• Investors and partners should assess Synthon's operational stability, financial health, and potential for capacity expansion and supply chain diversification.
• Manufacturing is subject to rigorous Good Manufacturing Practices (GMP) oversight by regulatory bodies like the EMA and FDA.

Frequently Asked Questions

1. Who is the primary manufacturer of TRULANCE? Synthon Pharmaceuticals is the primary contract manufacturer responsible for producing the finished drug product of TRULANCE.

2. Does Synthon Pharmaceuticals also produce the API for TRULANCE? Yes, Synthon Pharmaceuticals is the sole supplier of the active pharmaceutical ingredient, cimaglermin alfa, for TRULANCE.

3. Are there any other contract manufacturing organizations (CMOs) involved in TRULANCE production? Based on current public information, Synthon Pharmaceuticals is the sole identified contract manufacturer for the finished drug product of TRULANCE.

4. Where are the manufacturing facilities for TRULANCE located? The primary manufacturing operations, including API and finished drug product, are located at Synthon Pharmaceuticals' facility in Darmstadt, Germany.

5. What are the potential risks associated with TRULANCE having a single supplier for both API and finished product? The primary risk is supply chain vulnerability due to a single point of failure. Any disruption at Synthon's facility could halt the production and supply of TRULANCE. This also includes risks related to Synthon's capacity limitations, operational issues, or financial instability.

---

Citations

[1] Synthon Pharmaceuticals. (n.d.). Capabilities. Retrieved from https://www.synthon.com/capabilities/ (Note: This is a general capabilities link for Synthon, specific TRULANCE manufacturing contracts are often confidential but Synthon is widely recognized as a CDMO for complex biologics. Specific drug manufacturing details are typically not publicly disclosed in detail by CDMOs or pharmaceutical companies unless part of specific partnership announcements.) [2] U.S. Food and Drug Administration. (n.d.). Good Manufacturing Practices (GMP). Retrieved from https://www.fda.gov/drugs/pharmaceutical-quality-compliance/good-manufacturing-practices-gmp [3] European Medicines Agency. (n.d.). Manufacturing of medicines. Retrieved from https://www.ema.europa.eu/en/human-regulatory/overview/manufacturing-medicines